Fu-An Kang, Ph.D., is an accomplished synthetic, medicinal and process scientist and expert with extensive experiences in chemical and pharmaceutical research and development. After he obtained his Ph.D. in Organic Chemistry at Beijing Normal University in China, he joined Professor Yoshito Kishi’s group at Harvard University for his postdoc research in 1999. He developed the asymmetric Ni/Cr coupling methodology and contributed to the practical synthesis of the Halichondrin derived anticancer drug Eribulin (Halaven, approved in 2010) in the Harvard-Eisai collaboration. He joined Johnson & Johnson PRD in 2002 and worked on various therapeutic areas with demonstrated expertise ranging from drug discovery to drug development. He discovered a novel series of oxa-mifepristone-like steroids as highly selective progesterone receptor modulators, which are potentially useful for breast cancer treatment. His contribution to the chemical development of the SGLT2 inhibitor Canagliflozin (Invokana, approved in 2013) to treat type 2 diabetes received a Johnson & Johnson Platinum Encore Award. He discovered and developed the “Phosphonium Coupling”, a new chemical methodology for the direct arylation of tautomerizable heterocycles, which has found many applications in medicinal chemistry, process chemistry and material sciences in recent years. He also published an interesting mathematical interpretation for the classical empirical “Woodward UV Rules”. Since 2011, he has moved into the CRO/CMO/PRO industry as senior managers for the research, development and cGMP manufacturing of pharmaceuticals. He served as CSO at Santai Labs in China, and VP at Wilmington Pharmatech in the US. He joined TCRS/Abzena in 2015 and currently serves as Senior Director of Chemistry overseeing the research and development of medicinal compounds, API KG production, material synthesis, and ADC payload development. He has over 50 scientific publications in journals and patents.
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.